- Home
- CNTA vs NNNN Comparison
CNTA vs NNNN Comparison
Compare CNTA & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- NNNN
- Stock Information
- Founded
- CNTA 2020
- NNNN 2021
- Country
- CNTA United Kingdom
- NNNN Germany
- Employees
- CNTA N/A
- NNNN N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CNTA Health Care
- NNNN Health Care
- Exchange
- CNTA Nasdaq
- NNNN Nasdaq
- Market Cap
- CNTA 2.3B
- NNNN 2.2B
- IPO Year
- CNTA 2021
- NNNN 2025
- Fundamental
- Price
- CNTA $22.92
- NNNN $16.54
- Analyst Decision
- CNTA Strong Buy
- NNNN
- Analyst Count
- CNTA 9
- NNNN 0
- Target Price
- CNTA $31.75
- NNNN N/A
- AVG Volume (30 Days)
- CNTA 1.3M
- NNNN 39.0K
- Earning Date
- CNTA 11-05-2025
- NNNN 04-28-2026
- Dividend Yield
- CNTA N/A
- NNNN N/A
- EPS Growth
- CNTA N/A
- NNNN N/A
- EPS
- CNTA N/A
- NNNN 0.06
- Revenue
- CNTA $15,000,000.00
- NNNN $8,185,146.00
- Revenue This Year
- CNTA N/A
- NNNN N/A
- Revenue Next Year
- CNTA N/A
- NNNN N/A
- P/E Ratio
- CNTA N/A
- NNNN $340.17
- Revenue Growth
- CNTA 118.88
- NNNN 21.95
- 52 Week Low
- CNTA $9.60
- NNNN $5.18
- 52 Week High
- CNTA $25.42
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- CNTA 48.74
- NNNN 37.59
- Support Level
- CNTA $17.05
- NNNN $10.50
- Resistance Level
- CNTA $25.35
- NNNN $22.00
- Average True Range (ATR)
- CNTA 1.47
- NNNN 3.65
- MACD
- CNTA -0.21
- NNNN -0.33
- Stochastic Oscillator
- CNTA 71.72
- NNNN 30.77
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.